Welcome to: Beijing Dongfang Baitai Biotechnology Co., Ltd.

Oriental Baitai’s anti-cancer drug has received clinical trial approval!


[Summary Description]

Beijing Dongfang Baitai Biotechnology Co., Ltd. is an emerging biotechnology company focused on the research and development of humanized monoclonal antibodies. Its investigational product, the anti-VEGF humanized antibody JY028, recently received approval from the China Food and Drug Administration (CFDA) to proceed with clinical trials, marking a significant milestone that allows Dongfang Baitai to officially initiate clinical studies in China and take an important step toward product commercialization. This achievement also represents another major breakthrough for Dongfang Baitai, following its earlier receipt of clinical trial authorization for the long-acting diabetes biologic JY09.


Recommended News

Leave a Message Online Online Message


Submit